

**[For immediate release]**



**China Regenerative Medicine International Limited  
(Stock Code: 8158.HK)**

**Dr. Shi Weiyun, National People's Congress Deputy, "Acornea" Cornea  
Transplantation Expert of CRMI Proposed  
the Acceleration of the Application of New products of  
Biological Engineering Cornea**

Hong Kong, 7 March 2018 – **China Regenerative Medicine International Limited** ("China Regenerative Medicine" or "the Company", stock code: 8158.HK, together with its subsidiaries, collectively "the Group") is pleased to announce that the first meeting of China's 13th National People's Congress (NPC) opened at the Great Hall of the People in Beijing on 5 March. Dr. Shi Weiyun, Director of Shandong Eye Institute, Secretary of Party Committee, Dean of Shandong Eye Hospital, showed high concern in the issue of corneal blindness particularly the unsatisfied supply of corneal material against the huge demand by corneal-blindness patients in the PRC in his report. He suggested three proposals regarding corneal blindness to realize the replacement of human cornea donation with bio-engineering cornea.

Dr. Shi Weiyun is Director of Shangdong Eye Institute as well as a specialist in cornea transplantation of "Acornea" of CRMI. He indicated that eye health is an important part for people's health. Visual damage including blindness will severely affect people's health and living quality, which will increase the burden on families and society, threatening social and economic productivity. This is a public health and social issue affecting people's livelihood. He proposed to improve the shortage of corneal material across the country by enhancing citizen awareness of donation, improving the donation legislative and regulatory system, expanding the donation pipeline and strengthening the standardization of the eye bank. Moreover, specialized research about the cornea importation problem should be conducted in order to

optimize the supervision. Also, bio-engineering cornea research is suggested to be included in National Science and Technology Major Project, focusing on tackling the key issues so as to speed up the approval and application of new products and realize the replacement of human cornea donation with bio-engineering cornea.

Bio-engineering cornea "Acornea" is researched and developed by CRMI. It is the world's first bio-engineering cornea that has completed clinical trials and has been successfully launched to market. It is researched and developed independently by Chinese scientists with complete independent intellectual property rights, which solidifies China's global leading position in regenerative medicine research of corneal disease. The total effective rate of clinical trials of "Acornea" reached 94.44% with the healing effect close to donated cornea. In 2016, "Acornea" was reported by BBC as one of the five major scientific and technological revolutions from China. In the middle of last year, the Group has actively been expanding the clinical applications of its bioengineered cornea "Acornea" in ophthalmological surgeries. The approval from FDA allows the biomaterial of "Acornea" to be use in production of drainage pouch for Tube-Shunt Surgery for Glaucoma, which can effectively prevent from corrosion of the eye vessel, benefiting 82,000 patients every year.

Besides, CRMI established Joint Laboratory for Regenerative Medicine Technology of National Ophthalmic Engineering Center, which aims to promote the combination of scientific research and production and to coordinate international cooperation and scientific research of China's ophthalmic regenerative medicine; to develop the resources in business and academic through the cooperation with government and to enhance the recognition of the international business partners towards "Acornea". "Acornea" will enter the global market after attaining the international certification and performing well to build a solid foundation for the sustainable development of the Group.

-End-

### **About China Regenerative Medicine International Limited**

China Regenerative Medicine International Limited ("CRMI"), listed on The Stock Exchange of Hong Kong Limited on 18 July 2001 (Stock Code: 8158.HK), is a high-end new-technology

enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of CRMI ranges among five major sectors, namely tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and overseas business division. Headquartered in Hong Kong, CRMI has seven modernized manufacturing facilities in Xi'an, Shenzhen, Suzhou, Tianjin, Changzhou and Hong Kong, and has evolved into a pioneering enterprise in tissue engineering and regenerative medicine in China.

For more details, please visit [www.crmi.hk](http://www.crmi.hk)